April 15, 2014
By Reuters Staff
(Reuters) - The U.S. Food and Drug Administration has approved the injectable glucagon-like peptide-1 (GLP-1) agonist Tanzeum (albiglutide) for treating type 2 diabetes, in combination with diet and exercise.
Tanzeum from GlaxoSmithKline Plc will carry a warning on its label that tumors of the thyroid gland were observed in rodent studies with some drugs belonging to the same class. However, it is unknown whether Tanzeum causes thyroid C-cell tumors, the FDA said on its website.
The regulator also asked for post-marketing studies to test the drug's dosing, efficacy and safety in children, and to check for heart-related risks.
It also asked the company to identify any increase in medullary thyroid cancer cases related to Tanzeum.
The drug, given once weekly, was approved last month in Europe, where it will be marketed as Eperzan.
Analysts expect the drug to hit $430 million in sales by 2018, according to Thomson Reuters data.
Tanzeum belongs to the same class of injectable GLP-1 drugs as Victoza (liraglutide) from Novo Nordisk and Byetta (exenatide) and Bydureon (exenatide ER) from AstraZeneca.
Type 2 diabetes affects about 24 million people and accounts for more than 90% of diabetes cases diagnosed in the United States, the FDA said.
(c) Copyright Thomson Reuters 2014. Click For Restrictions - http://about.reuters.com/fulllegal.asp